Liminal Biosciences Inc
LMNL
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.62M
Close$
$12.10
42.3% upside
Current Fair Value
42.3% upsideUndervalued by 42.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $27.62 Million |
|---|---|
| Enterprise Value | $9.52 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-341.8 |
| Beta | 1.03 |
| Outstanding Shares | 84,600 |
Return
| Return on Equity | 1.65% |
|---|---|
| Return on Assets | 1.11% |
| Return on Invested Capital | -151.51% |
Valuation & Multiples
| P/E Ratio | -0.03 |
|---|---|
| PEG | -0.02 |
| Price to Sales | 1.7 |
| Price to Book Ratio | 0.03 |
| Enterprise Value to Revenue | 19.34 |
| Enterprise Value to EBIT | -0.28 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Liminal Biosciences Inc
CEO: Kenneth Galbraith Liminal BioSciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases of high unmet medical need, primarily related to fibrosis, inc...